zinbryta
biogen idec ltd - daclizumab - roztrúsená skleróza - imunosupresíva - zinbryta je indikovaný u dospelých pacientov pri liečbe recidivujúce formy sklerózy multiplex (rms).
ocrevus
roche registration gmbh - ocrelizumab - roztrúsená skleróza - imunosupresíva - liečba dospelých pacientov s recidivujúcimi formami sklerózy multiplex (rms) s aktívnou chorobou definovanou klinickými alebo zobrazovacími znakmi. liečba dospelých pacientov s včasnou primárne progresívny roztrúsená skleróza (ppms) pokiaľ ide o ochorenia, trvanie a stupeň zdravotného postihnutia, a s zobrazovacie vlastnosti charakteristické pre zápalové činnosť.
kesimpta
novartis ireland ltd - ofatumumab - roztrúsená skleróza, recidivujúce-odosielajúcej - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.
plegridy
biogen netherlands b.v. - peginterferón beta-1a - roztrúsená skleróza - immunostimulants, - liečba relapsujúcej remitujúcej roztrúsenej sklerózy u dospelých pacientov.
blincyto
amgen europe b.v. - blinatumomab - prekurzorová bunková lymfoblastická leukémia-lymfóm - antineoplastické činidlá - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
fingolimod grindeks 0,5 mg tvrdé kapsuly
as grindeks, lotyšsko - fingolimod - 59 - immunopraeparata
imatinib grindeks 100 mg tvrdé kapsuly
as grindeks, lotyšsko - imatinib - 44 - cytostatica
ursogrix 250 mg tvrdé kapsuly
as grindeks, lotyšsko - kyselina ursodeoxycholová - 43 - choleretica, cholekinetica
escitalopram grindeks 20 mg filmom obalené tablety
as grindeks, lotyšsko - escitalopram - 30 - antidepressiva
escitalopram grindeks 10 mg filmom obalené tablety
as grindeks, lotyšsko - escitalopram - 30 - antidepressiva